# Centre hospitalier universitaire de Québec

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/centre-hospitalier-universitaire-de-quebec/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 78.7 |
| Citations | 900,465 |
| City | Québec |
| Country | CA |
| Description | Centre hospitalier universitaire de Québec is a research organisation in Québec, CA. OpenAlex records 8,059 works and 900,465 citations for it. 1,635 researchers list it as their most recent affiliation. |
| Homepage | https://www.chudequebec.ca |
| OpenAlex ID | https://openalex.org/I4210093650 |
| Region | Quebec |
| Researchers | 1,635 |
| ROR ID | https://ror.org/006a7pj43 |
| Type | healthcare |
| Works | 8,059 |

## University papers

- [Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma](https://scholariq.org/papers/pembrolizumab-as-second-line-therapy-for-advanced-urothelial-carcinoma/)
- [A Phase 3 Trial of Bevacizumab in Ovarian Cancer](https://scholariq.org/papers/a-phase-3-trial-of-bevacizumab-in-ovarian-cancer/)
- [Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial](https://scholariq.org/papers/olaparib-tablets-as-maintenance-therapy-in-patients-with-platinum-sensitive/)
- [Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial](https://scholariq.org/papers/standard-chemotherapy-with-or-without-bevacizumab-for-women-with-newly-diagnosed/)
- [Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial](https://scholariq.org/papers/pembrolizumab-alone-or-combined-with-chemotherapy-versus-chemotherapy-as-first/)
- [Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial](https://scholariq.org/papers/olaparib-combined-with-chemotherapy-for-recurrent-platinum-sensitive-ovarian/)
- [Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial](https://scholariq.org/papers/durvalumab-alone-and-durvalumab-plus-tremelimumab-versus-chemotherapy-in/)
- [Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials](https://scholariq.org/papers/neoadjuvant-chemotherapy-versus-debulking-surgery-in-advanced-tubo-ovarian/)
- [Simple versus Radical Hysterectomy in Women with Low-Risk Cervical Cancer](https://scholariq.org/papers/simple-versus-radical-hysterectomy-in-women-with-low-risk-cervical-cancer/)
- [Conditional Survival After Radical Cystectomy for Bladder Cancer: Evidence for a Patient Changing Risk Profile over Time](https://scholariq.org/papers/conditional-survival-after-radical-cystectomy-for-bladder-cancer-evidence-for-a/)

## University top topics

Showing 8 of 25.

- [Advanced Radiotherapy Techniques](https://scholariq.org/topics/advanced-radiotherapy-techniques/)
- [BRCA gene mutations in cancer](https://scholariq.org/topics/brca-gene-mutations-in-cancer/)
- [Respiratory viral infections research](https://scholariq.org/topics/respiratory-viral-infections-research/)
- [Prostate Cancer Diagnosis and Treatment](https://scholariq.org/topics/prostate-cancer-diagnosis-and-treatment/)
- [Prostate Cancer Treatment and Research](https://scholariq.org/topics/prostate-cancer-treatment-and-research/)
- [Estrogen and related hormone effects](https://scholariq.org/topics/estrogen-and-related-hormone-effects/)
- [HIV Research and Treatment](https://scholariq.org/topics/hiv-research-and-treatment/)
- [Endometrial and Cervical Cancer Treatments](https://scholariq.org/topics/endometrial-and-cervical-cancer-treatments/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.